e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Hot topics on airway diseases: new horizons in treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
Guy Brusselle (Ghent, Belgium), Guy Brusselle, Matthew Germinaro, Sherrine Eid, James Zangrilli
Source:
International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Session:
Hot topics on airway diseases: new horizons in treatment
Session type:
Oral Presentation
Number:
287
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Guy Brusselle (Ghent, Belgium), Guy Brusselle, Matthew Germinaro, Sherrine Eid, James Zangrilli. LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils. Eur Respir J 2015; 46: Suppl. 59, 287
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement
Source: Annual Congress 2013 –Origins and diagnosis of asthma
Year: 2013
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014
Asthma control, symptoms and exacerbations across treatment levels in patients with asthma
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013
Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis
Source: International Congress 2015 – Epidemiological studies of asthma and allergy
Year: 2015
LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients
Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities
Year: 2016
LATE-BREAKING ABSTRACT: Serum periostin as a valuable biomarker of comorbid chronic rhinosinusitis in patients with asthma
Source: International Congress 2016 – Molecular immunology of the lung
Year: 2016
LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
Elevated blood eosinophil is a risk factor for future exacerbations in asthmatic children
Source: International Congress 2014 – Paediatric asthma: markers and molecules
Year: 2014
Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma
Source: International Congress 2016 – Phenotyping asthma
Year: 2016
Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013
LATE-BREAKING ABSTRACT: Is treatment with inhaled corticosteroids in asthma associated with hospitalisations because of pneumonia?
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016
LATE-BREAKING ABSTRACT: Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The copenhagen general population study
Source: International Congress 2015 – New observations in respiratory epidemiology
Year: 2015
LATE-BREAKING ABSTRACT: Vocal cord dysfunction (VCD) in mild and severe asthma
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Exacerbations in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS, NHLBI) are associated with sputum eosinophilia but not blood eosinophilia
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene
Source: International Congress 2014 – COPD exacerbations
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept